Latest Administration News

Astute Metals NL has announced a significant JORC-compliant Exploration Target for its Red Mountain Lithium Project in Nevada, highlighting substantial lithium potential and outlining aggressive drilling plans for 2025.

RareX has finalized a critical access agreement with Deep Yellow and secured two additional licenses, enabling a fully optimised drilling program targeting carbonatite intrusions at the Khaleesi Project.

Titanium Sands Limited has raised $500,000 through a placement to advance environmental approvals and mining licence progress for its Mannar Island Heavy Mineral Project in Sri Lanka.

Island Pharmaceuticals has successfully completed patient dosing in the Phase 2b therapeutic arm of its PROTECT clinical trial for ISLA-101, targeting dengue fever treatment. High-level results are expected within two months, potentially advancing a significant antiviral candidate.

EMVision Medical Devices has secured US ethics approval for its pivotal multi-centre trial of the EMVision emu™ brain scanner, paving the way for a March 2025 trial start aimed at FDA clearance.

Suncorp Group Limited delivered a robust half-year performance with a $1.1 billion net profit, driven by favourable natural hazard conditions and the strategic sale of Suncorp Bank. The insurer plans a substantial $4.1 billion return to shareholders, underscoring its strong capital position and growth ambitions.

Sarama Resources has completed the second tranche of its A$2 million equity placement, issuing options to institutional investors after shareholder approval. The funds are earmarked for advancing exploration and supporting working capital.

Memphasys has completed the final patient visit in its Felix™ clinical trial, with data lock expected within two weeks and preliminary results slated for early March 2025. This milestone paves the way for CE Mark submission and imminent commercialisation in Europe.

Resouro Strategic Metals Inc. posted a $5.28 million net loss for the nine months ended December 31, 2024, reflecting increased exploration and administrative expenses as it advances its Tiros Titanium and Rare Earth Elements Project. The company bolstered its balance sheet with a successful ASX dual listing and private placements but faces ongoing challenges to sustain operations.

CSL Limited reported a solid half-year performance with 5% revenue growth and a 7% rise in net profit, driven by strong demand in its Behring and Vifor segments despite challenges in Seqirus. The company reaffirmed its full-year NPATA guidance of 10-13%, signaling confidence in its operational momentum.

CSL Limited reported a solid 5% revenue increase and 6% rise in net profit after tax for the half year ended December 2024, underpinned by robust performance in its plasma therapies business despite headwinds in its influenza vaccine segment.

Anagenics reports a marked reduction in operating cash outflow and expenses following a strategic restructuring, setting the stage for improved financial stability in the coming quarter.